AIA Group Ltd Has $6.17 Million Position in Amgen Inc. $AMGN

AIA Group Ltd boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 61.6% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 21,876 shares of the medical research company’s stock after purchasing an additional 8,341 shares during the quarter. AIA Group Ltd’s holdings in Amgen were worth $6,173,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Evelyn Partners Investment Management LLP bought a new stake in shares of Amgen during the 2nd quarter worth $32,000. Howard Hughes Medical Institute acquired a new position in Amgen in the 2nd quarter valued at $32,000. Cloud Capital Management LLC bought a new position in Amgen in the 3rd quarter worth $34,000. Saranac Partners Ltd acquired a new position in Amgen during the 3rd quarter worth $37,000. Finally, AXS Investments LLC acquired a new position in Amgen during the 3rd quarter worth $42,000. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Down 2.7%

NASDAQ AMGN opened at $351.48 on Thursday. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $391.29. The stock has a market cap of $189.47 billion, a PE ratio of 24.70, a PEG ratio of 3.58 and a beta of 0.45. The firm has a 50-day simple moving average of $359.46 and a 200 day simple moving average of $326.94. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.76 by $0.53. The firm had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same period in the previous year, the company posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, research analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be given a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.9%. Amgen’s payout ratio is currently 70.84%.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Analysts lifted Amgen’s fair value amid optimism around obesity candidate MariTide and execution, which supports a stronger medium-term outlook for earnings. How The Amgen (AMGN) Narrative Is Shifting With MariTide Hopes And Exclusivity Concerns
• Positive Sentiment: Billionaire Ken Fisher increased his Amgen stake, a signal of institutional confidence that can support investor sentiment. Amgen Inc. (AMGN): Billionaire Ken Fisher Doubles Bullish Position
• Neutral Sentiment: Short-interest print shows zero shares (and NaN change), which appears to be a reporting error; it doesn’t offer actionable insight into current positioning.
• Neutral Sentiment: Sector/biotech financing note — Crossbow raised $77M for an oncology T‑cell engager program; industry capital flow can influence sentiment but it doesn’t directly affect Amgen’s fundamentals. Crossbow raises $77M for new cancer immunotherapies
• Negative Sentiment: Report says Amgen will join TrumpRx and offer an ~80% discount on Amjevita — a move that could pressure revenue/margins for that product and raise investor concern about pricing concessions. Amgen, GSK Set To Join TrumpRx Offering Deep Prescription Drug Discounts: Report
• Negative Sentiment: Market headlines reporting that AMGN closed lower amid a broader market uptick — confirms the stock is underperforming today and may be reacting to the items above. Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on AMGN shares. Mizuho raised their price target on Amgen from $280.00 to $295.00 and gave the company an “outperform” rating in a research report on Tuesday, February 10th. The Goldman Sachs Group increased their target price on Amgen from $403.00 to $415.00 and gave the company a “buy” rating in a research note on Wednesday, February 4th. HSBC reaffirmed a “buy” rating and issued a $425.00 target price on shares of Amgen in a report on Wednesday, December 10th. Sanford C. Bernstein downgraded Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price target on the stock. in a research report on Tuesday, January 20th. Finally, Erste Group Bank upgraded Amgen from a “hold” rating to a “buy” rating in a report on Friday, December 5th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $354.00.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.